<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48936">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469155</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-007-302</org_study_id>
    <nct_id>NCT02469155</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <brief_summary>
    <textblock>
      The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind,
      parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed
      with schizophrenia having an acute exacerbation of psychosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale Total Score</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Syndrome Scale Subscales</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">696</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>20 mg ITI-007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60 mg ITI-007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg ITI-007 administered orally as formulated capsules once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally as visually-matched capsules once daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone administered orally as visually-matched over-encapsulated tablet once daily for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITI-007</intervention_name>
    <arm_group_label>20 mg ITI-007</arm_group_label>
    <arm_group_label>60 mg ITI-007</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <arm_group_label>Risperidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis
             of schizophrenia

          -  experiencing an acute exacerbation of psychosis

        Exclusion Criteria:

          -  any subject unable to provide informed consent

          -  any female subject who is pregnant or breast-feeding

          -  any subject judged to be medically inappropriate for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberly Vanover, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Intra-Cellular Therapies, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>March 9, 2017</lastchanged_date>
  <firstreceived_date>June 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
